Literature DB >> 18446787

Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies.

Patty Tam1, Radhia Mahfoud, Anita Nutikka, Aye Aye Khine, Beth Binnington, Paul Paroutis, Clifford Lingwood.   

Abstract

Although verotoxin-1 (VT1) and verotoxin-2 (VT2) share a common receptor, globotriaosyl ceramide (Gb(3)), VT2 induces distinct animal pathology and is preferentially associated with human disease. Moreover VT2 cytotoxicity in vitro is less than VT1. We therefore investigated whether these toxins similarly traffic within cells via similar Gb(3) assemblies. At 4 degrees C, fluorescent-VT1 and VT2 bound both coincident and distinct punctate surface Gb(3) microdomains. After 10 min at 37 degrees C, similar distinct/coincident micropunctate intracellular localization was observed. Most internalized VT2, but not VT1, colocalized with transferrin. After 1 h, VT1 and VT2 coalesced during retrograde transport to the Golgi. During prolonged incubation (3-6 h), VT1, and VT2 (more slowly), exited the Golgi to reach the ER/nuclear envelope. At this time, VT2 induced a previously unreported, retrograde transport-dependent vacuolation. Cell surface and intracellular VT1 showed greater detergent resistance than VT2, suggesting differential 'raft' association. >90% (125)I-VT1 cell surface bound, or added to detergent-resistant cell membrane extracts (DRM), was in the Gb(3)-containing sucrose gradient 'insoluble' fraction, whereas only 30% (125)I-VT2 was similarly DRM-associated. VT1 bound more efficiently to Gb(3)/cholesterol DRMs generated in vitro. Only VT1 binding was inhibited by high cholesterol/Gb(3) ratios. VT2 competed less effectively for (125)I-VT1/Gb(3) DRM-binding but only VT2-Gb(3)/cholesterol DRM-binding was augmented by sphingomyelin. Differential VT1/VT2 Gb(3) raft-binding may mediate differential cell binding/intracellular trafficking and cytopathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446787     DOI: 10.1002/jcp.21456

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  30 in total

1.  The functional and molecular characterisation of human embryonic stem cell-derived insulin-positive cells compared with adult pancreatic beta cells.

Authors:  C L Basford; K J Prentice; A B Hardy; F Sarangi; S J Micallef; X Li; Q Guo; A G Elefanty; E G Stanley; G Keller; E M Allister; M C Nostro; M B Wheeler
Journal:  Diabetologia       Date:  2011-11-11       Impact factor: 10.122

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

3.  Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.

Authors:  Jing Huang; David G Motto; David R Bundle; J Evan Sadler
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

4.  A Conserved Structural Motif Mediates Retrograde Trafficking of Shiga Toxin Types 1 and 2.

Authors:  Andrey S Selyunin; Somshuvra Mukhopadhyay
Journal:  Traffic       Date:  2015-11-02       Impact factor: 6.215

Review 5.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

6.  Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.

Authors:  Patrick Cherubin; Dennis Fidler; Beatriz Quiñones; Ken Teter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

7.  Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.

Authors:  Steven D Zumbrun; Leanne Hanson; James F Sinclair; James Freedy; Angela R Melton-Celsa; Jaime Rodriguez-Canales; Jeffrey C Hanson; Alison D O'Brien
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

8.  Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells.

Authors:  Ivan U Kouzel; Gottfried Pohlentz; Wiebke Storck; Lena Radamm; Petra Hoffmann; Martina Bielaszewska; Andreas Bauwens; Christoph Cichon; M Alexander Schmidt; Michael Mormann; Helge Karch; Johannes Müthing
Journal:  J Lipid Res       Date:  2012-12-17       Impact factor: 5.922

9.  The ether lipid precursor hexadecylglycerol protects against Shiga toxins.

Authors:  Jonas Bergan; Tore Skotland; Anne Berit Dyve Lingelem; Roger Simm; Bjørn Spilsberg; Toril Lindbäck; Tuulia Sylvänne; Helena Simolin; Kim Ekroos; Kirsten Sandvig
Journal:  Cell Mol Life Sci       Date:  2014-04-18       Impact factor: 9.261

10.  Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling.

Authors:  Beth Binnington; Long Nguyen; Mustafa Kamani; Delowar Hossain; David L Marks; Monique Budani; Clifford A Lingwood
Journal:  Glycobiology       Date:  2015-09-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.